Gujarat Themis Biosyn working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
174.55×174.55×75.16×
101.42×101.42×75.61×
437.50×437.50×218.21×
−161.53×−161.53×−67.44×
18.05×17.23×4.80×
0.41×0.41×0.50×
1.04×1.04×1.87×
0.65×0.65×1.32×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GUJTHEM₹375.80

Gujarat Themis Biosyn Limited

· Pharma & Health
₹ CrorePeersRPGLIFEGUFICBIOORCHPHARMAUNICHEMLABFDCIOLCPMOREPENLABINNOVACAPMcap ₹4,095 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)75.16174.55174.55
Receivable Days (DSO)75.61101.42101.42
Payable Days (DPO)218.21437.50437.50
Cash Conversion Cycle (days)-67.44-161.53-161.53
Working Capital Turnover4.8017.2318.05
Asset Turnover0.500.410.41
Cash Conversion (CFO/Net Income)1.871.041.04
CFO/EBITDA1.320.650.65
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.